VolitionRx Limited (NYSE:VNRX) stock is surging on Thursday after the diagnostics company reported a 112% year-over-year revenue surge in the first half of 2026, reaching $1.4 million as it expanded its clinical and commercial operations.
The multi-national epigenetics firm demonstrated strong momentum across its core diagnostic verticals, including sepsis monitoring, human oncology detection, and companion animal health, positioning the company to address total market opportunities exceeding $26 billion.
Sepsis Validations And Point-Of-Care Progress
In sepsis, Critical Care Medicine published independent, peer-reviewed data confirming that the Nu.Q NETs H3.1 biomarker serves as an independent predictor of 28-day mortality and renal replacement therapy.
This validates the assay’s clinical utility for severe sepsis, which features a $2.8 billion total addressable market. Volition is preparing for the September 2026 recruitment start of France’s $7.3 million government-backed DETECSEPS evaluation.
Simultaneously, the company confirmed clinical correlation for its bedside finger-prick lateral flow prototype, potentially broadening testing beyond centralized laboratories.
Cancer Detection Milestones And Reimbursement Strategy
In cancer care, Volition published clinical data demonstrating that its Capture-Seq platform identified over 95% of Stage I and II early cancers with 95% specificity, underpinning an annualized $23 billion early detection opportunity.
Additionally, the business actively prepares a conditional reimbursement filing in France for its lung cancer test by the end of 2026 following initial pre-submission meetings.
Veterinary Pipeline Progress And Commercial Partnerships
The company also broadened its veterinary pipeline by submitting a manuscript for its Nu.Q Vet feline lymphoma test. Upon peer-reviewed publication, this study will unlock an anticipated $5 million contractual milestone payment.
To support global distribution, Volition transferred its Nu.Q NETs assay to Sysmex Corporation’s platform and maintains active discussions with more than twelve major liquid biopsy and diagnostic firms.
VNRX Price Action: VolitionRX shares were up 100.47% at $0.68 during premarket trading on Thursday. The stock is trading near its 52-week low of $0.32, according to Benzinga Pro data.
Image Via Shutterstock
